Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 4Ureteral Neoplasms 3Urologic Neoplasms 2Urethral Neoplasms 2Carcinoma, Transitional Cell 2Urothelial Cancer 1Metastatic Urothelial Cancer 1

Interventions

enfortumab vedotin 3vinflunine 1pembrolizumab 1Paclitaxel 1Gemcitabine 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Ureteral Neoplasms × enfortumab vedotin × Clear all
NCT03288545 2026-03-24

EV-103

Astellas Pharma Inc

Phase 1/2 Terminated
348 enrolled 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT03219333 2024-08-27

EV-201

Astellas Pharma Inc

Phase 2 Completed
219 enrolled 32 charts 2 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡